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Abstract
Background: The protozoan Trypanosoma cruzi is the causative agent of Chagas disease. There are no vaccines or effective
treatment, especially in the chronic phase when most patients are diagnosed. There is a clear necessity to develop new
drugs and strategies for the control and treatment of Chagas disease. Recent papers have suggested the ecto-nucleotidases
(from CD39 family) from pathogenic agents as important virulence factors. In this study we evaluated the influence of Ecto-
Nucleoside-Triphosphate-Diphosphohydrolase (Ecto-NTPDase) activity on infectivity and virulence of T. cruzi using both in
vivo and in vitro models.
Methodology/Principal Findings: We followed Ecto-NTPDase activities of Y strain infective forms (trypomastigotes)
obtained during sequential sub-cultivation in mammalian cells. ATPase/ADPase activity ratios of cell-derived
trypomastigotes decreased 3- to 6-fold and infectivity was substantially reduced during sequential sub-cultivation.
Surprisingly, at third to fourth passages most of the cell-derived trypomastigotes could not penetrate mammalian cells and
had differentiated into amastigote-like parasites that exhibited 3- to 4-fold lower levels of Ecto-NTPDase activities. To
evidence the participation of T. cruzi Ecto-NTPDase1 in the infective process, we evaluated the effect of known Ecto-
ATPDase inhibitors (ARL 67156, Gadolinium and Suramin), or anti-NTPDase-1 polyclonal antiserum on ATPase and ADPase
hydrolytic activities in recombinant T. cruzi NTPDase-1 and in live trypomastigotes. All tests showed a partial inhibition of
Ecto-ATPDase activities and a marked inhibition of trypomastigotes infectivity. Mice infections with Ecto-NTPDase-inhibited
trypomastigotes produced lower levels of parasitemia and higher host survival than with non-inhibited control parasites.
Conclusions/Significance: Our results suggest that Ecto-ATPDases act as facilitators of infection and virulence in vitro and in
vivo and emerge as target candidates in chemotherapy of Chagas disease.
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Introduction
Trypanosoma cruzi is the etiologic agent of Chagas disease, an
endemic zoonosis present in some countries of South and Central
Americas. WHO estimates suggested that 100 million people
remain at risk of acquiring this infection [1]. There are no vaccines
or effective treatment for this disease, especially in the chronic
phase [2]. Many compounds are potential candidates to be used in
the treatment for Chagas disease, such as TAK-187, D0870,
albaconazole and allopurinol [2]. In spite of these, there is a clear
necessity to develop new drugs and strategies for the control and
treatment of Chagas disease [2]. From this point of view, virulence
biomolecules, in particular those secreted or ecto-localized at the
parasite’s plasma membrane seem to be good targets. The
concentrations of extra cellular nucleotides and their derivative
molecules, such as adenosine and inosine are linked to ecto-
nucleotidase activities of cells [3,4]. The role of ecto-nucleotidases
as the major biomolecules involved in the control of purinergic
signaling were demonstrated in various models, such as the
dominant role of CD39 in the modulation of inflammation and
immune response in the Langerhans cells [5] and in cardioprotec-
tion and protective responses to hypoxia/ischemia in murine
model [6,7]. ATP has been previously demonstrated as a ‘‘danger’’
extracellular signal induced by pathogen infection or injury, and it
is able to trigger different cellular events such as proliferation,
differentiation and chemotaxis, release of cytokines or lysosomal
constituents, and generation of reactive oxygen or nitrogen species
[4]. Some authors believe that a high ecto-ATPase activity of
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organisms more virulent because they interfere with extracellular
ATP signals [8–11].
Members of Ecto-NTPDase family are nucleotidases able to
hydrolyze 59-nucleoside tri- and/or diphosphates; the main role of
these enzymes is the termination of purinergic signaling [12].
NTPDases are ubiquitous and were previously shown in other
parasites including the trypanosomatides of genus Leishmania and
in T. brucei [13–16]. Recent papers have suggested the ecto-
nucleotidases from pathogenic agents, including parasites, and in a
special way the Ecto-NTPDases (from CD39 family) as important
virulence factors [9,14,17–21]. This hypothesis was clearly
evidenced in Toxoplasma gondii and Legionela pneumophila [8,11,22].
In T. gondii the NTPase, a member of CD39 family, is produced as
a soluble low activity tetrameric enzyme in the parasitophorous
vacuole. Activation of this enzyme by dithiol agent (DTT) leads to
depletion of host ATP levels and rapid exit of intracellular
parasites from infected cells [8]. These data support the idea that
activation of NTPase is an event related with the end of one
intracellular parasite life cycle and the start of another cellular
infection. In other words, NTPase activity would act as a timer
and is crucial to T. gondii infection. In addition, Naakar and
coworkers showed that lowering the expression of NTPDase by
RNA antisense technology inhibits T. gondii proliferation in in vitro
infection [22]. In L. pneumophila it was demonstrated that an Ecto-
NTPDase, similar to CD39, is essential for intracellular bacterial
multiplication. The authors showed that this pathogenic bacterium
has two Ecto-NTPDases (lpg0971 and lpg1905), and only the
product of lpg1905 is implicated with in vitro intracellular
multiplication and mice virulence [11,23].
T. cruzi is another example of pathogenic agent in which Ecto-
NTPDase was suggested as a virulence factor. The first evidence of
an ecto-nucleotidase at the T. cruzi surface was the demonstration
of an ecto-ATPase activity in intact parasites that was partially
sensitive to 4,49-diisothiocyanatestilbene-2,29-disulfonic acid
(DIDs) [24]. Subsequently, three papers showed evidence that
surface T. cruzi ecto-ATPase could modulate parasite-host
interaction [10,17,25]. Bisaggio and co-workers [10] showed that
treatment with ecto-ATPase inhibitors (Suramin and DIDs) lead to
inhibition of ATPase activity, adhesion and internalization of
parasites in macrophage in vitro infection [10]. In addition, the
over-expression of ecto-ATPase activity was followed by a
dramatic increase in parasite adhesion to resident macrophages.
In 2004 our group obtained the first biochemical characteriza-
tion and immunolocalization of an Ecto-NTPDase on the T. cruzi
surface [17]. In the same work we isolated a cDNA encoding an
Ecto-NTPDase homologue to CD39 family enzymes. Because
trypomastigotes presented higher levels of ecto-ATPase activity
than epimastigotes and because the literature clearly pointed to
ATP as a pro-inflammatory molecule we suggested that ecto-
ATPase activity could be related with parasite virulence [17].
In the present work, we show that a high ratio of ecto-ATP/
ADP hydrolysis is important to maintain the capacity of parasites
to infect mammalian VERO cells. Additionally, Ecto-NTPDase
inhibition modulates infectivity and virulence to mice, suggesting
that NTPDase is a facilitator of T. cruzi infection.
Methods
Reagents
Giemsa was purchased from Merck (D-6100 Darmstadt,
Germany). ARL67156, Suramin, GdCl3, ATP, ADP and AMP
were purchased from Sigma Chemical Co. (St. Louis, MO).
Distilled water was deionized using a MilliQ system (Millipore
Corp., Bedford, MA) and was used in the preparation of all
solutions.
Parasites
Different T. cruzi strains, Y, CL, Be-62 (all from the T. cruzi II
lineage) and CL Brener (a hybrid cloned strain) were maintained
for successive blood passages in mice.
Cell culture infections
Vero cells lines (carcinoma-derived African green monkey
fibroblast cells) were seeded in 75 cm
2 flasks at a density of 5610
4
and sustained in RPMI 1640 medium (GIBCO BRL) supple-
mented with 5% fetal calf serum (FCS, from CULTILAB,
Campinas, SP, Brazil) and 1 mM L-glutamine (Sigma Aldrich).
After 48 h of plating, the cultures were infected with bloodstream
Y strain trypomastigotes harvested from T. cruzi-infected Swiss
mice by orbital venous sinus puncture on the day of peak
parasitemia employing a parasite/host cell ratio of 10:1. After
infection the cell cultures were maintained at 37uCi n5 %C O 2
atmosphere for 24 h for parasite internalization. After this time,
cells were washed three times with phosphate buffered saline (PBS)
solution, RPMI medium with 1% fetal calf serum (15 mL) was
added and cells were incubated at 33uC, 5% CO2 atmosphere, for
completion of the intracellular cell cycle of parasites. Vero cell-
derived trypomastigotes were isolated from culture supernatants of
infected cells after centrifugation at 25006g for 15 min. The
recently released cell-derived trypomastigotes were used for
infection of new cells grown in 75 cm
2 flasks employing a
parasite/host cell ratio of 10:1 and maintained for four sub-
cultivation passages in Vero cells.
Parasites derived from cells infected with bloodstream trypo-
mastigotes were called trypomastigotes of first cell passage (P1),
and those obtained from the successive sub-inoculations per-
formed with parasites derived from Vero cells were denominated
trypomastigotes of 2
nd,3
rd and 4
th passages (P2, P3, P4).
CL, Be-62 or CL-Brener parasites were recovered only after the
first passage (P1), Y strain parasites were recovered in P1 for ‘‘in
vitro’’ infectivity assays and in vivo infectivity and virulence
determination using Swiss mice as experimental model. After-
wards the Y strain was maintained until the fourth passage in the
continuous cultivation assay.
Author Summary
The protozoan Trypanosoma cruzi is the causative agent of
Chagas disease, an endemic zoonosis present in some
countries of South and Central Americas. The World Health
Organization estimates that 100 million people are at risk
of acquiring this disease. The infection affects mainly
muscle tissues in the heart and digestive tract. There are
no vaccines or effective treatment, especially in the chronic
phase when most patients are diagnosed, which makes a
strong case for the development of new drugs to treat the
disease. In this work we evaluate a family of proteins called
Ecto-Nucleoside-Triphosphate-Diphosphohydrolase (Ecto-
NTPDase) as new chemotherapy target to block T. cruzi
infection in mammalian cells and in mice. We have used
inhibitors and antibodies against this protein and demon-
strated that T. cruzi Ecto-NTPDases act as facilitators of
infection in mammalian cells and virulence factors in mice
model. Two of the drugs used in this study (Suramin and
Gadolinium) are currently used for other diseases in
humans, supporting the possibility of their use in the
treatment of Chagas disease.
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Intact live parasites were washed twice in 0.9% NaCl and
suspended (1.0610
8 cells/ml) in nucleotidase reaction medium
without nucleotides (116 mM NaCl, 5.4 mM KCl, 5.6 mM D-
glucose, 50 mM Hepes-Tris buffer, pH 7.2). The assays were
carried out in 125 mL total reaction volume. The reactions were
started with the addition of 2.5 mM ATP or ADP, in the presence
of 5 mM MgCl2 and were carried out as detailed elsewhere [14].
For the in vitro hydrolytic activity assays performed in the
presence of specific ecto-ATPase inhibitors or polyclonal antise-
rum anti-NTPDase-1, parasites were exposed during the entire
experimental time to the concentrations described in the Results.
The ecto-nucleotidase activities were determined by measurement
of inorganic phosphate (Pi) released to the medium after 1 hour of
incubation at 37uC [26].
Bacterial heterologous expression and purification of T.
cruzi NTPDase-1
The recombinant T. cruzi apyrase NTPDase-1 (Accession
No. AY540630) was expressed in bacterial heterologous system
by transfer of the cDNA (1770 bp) encoding the predicted soluble
portion of T. cruzi NTPDase-1 to the expression vector pET21b
(Novagen). Cloning in the correct frame was confirmed by partial
sequencing of recombinant plasmid, using T3 and T7 primers and
BigDyeET-terminator kit in the MegaBace 500 apparatus,
according to the manufacturer (GE Amersham Biosciences). The
cloned sequence excluded the portion encoding the previously
predicted putative amino-terminal signal peptide [17]. The
recombinant plasmid pET21b-Tc-NTPDase-1 was used for
transforming Escherichia coli BL21 (DE3). This vector adds a
hexa-histidine sequence (Hexa-HIS) at the carboxyl-terminal
portion of the resulting fusion protein, a tag that was used as
target for purification of recombinant protein using nickel affinity
chromatography Ni-NTA-agarose (GE-Amersham). Protein ex-
pression was induced with 1 mM IPTG during 1 hour at 37uC
and 200 rpm. Purification and protein refolding were performed
following previously described protocols [27].
Anti-T. cruzi-NTPDase-1 polyclonal antiserum production
The purified recombinant protein (rNTPDase-1) was used for
producing polyclonal antiserum by immunization of a female
rabbit. Previous to the immunization a blood sample was obtained
(3 mL) from the ear marginal vein (negative control). Purified
recombinant NTPDase-1 (0.5 mg in 0.5 mL complete Freund’s
adjuvant- Sigma) was inoculated by intradermal route. After three
weeks, another dose was inoculated (0.5 mg NTPDase-1 in
0.5 mL incomplete Freund’s adjuvant-Sigma). The immune serum
was recovered after an interval of 15 days. Blood was collected by
puncture of the ear marginal vein and centrifuged at 3000 rpm for
10 min at room temperature; the serum supernatant was
distributed in 1.5 ml aliquots. The pre-immune serum and
immune antiserum were used in western blotting analysis and
only immune serum was able to recognize the recombinant
NTPDase-1 (data not shown). Both sera were treated for the
complete inactivation of the complement system (CS) in order to
be used in ‘‘in vitro’’ infectivity assays and NTPDase-1 inhibition
assays. For this purpose, the pre-immune and immune sera were
warmed to 56uC for 30 min. After CS inactivation these samples
were stored in aliquots at 220uC.
T. cruzi mammalian cell invasion assays (Infectivity assays)
T. cruzi Y strain [28] was maintained cyclically in mice as
described above. VERO cells were grown at 37uC in RPMI 1640
medium (Sigma) supplemented with 5% fetal calf serum,
garamycin (10 mg/ml) in a humidified 5% CO2 atmosphere. In
vitro host cell invasion assays were carried out as detailed
elsewhere [29], using first passage trypomastigotes (P1). Briefly,
5610
5 trypomastigotes from Y strain were placed in each well of
24-well plates containing 13-mm round glass cover slips coated
with 5610
4 Vero cells (10:1). After 24 h of infection, the cover slips
were washed three times with 0.9% saline and stained with
Giemsa (Merck). The numbers of infected cells and amastigotes
per infected cell were counted in at least 300 cells, in
quadruplicate. In experiments using trypomastigotes treated with
NTPDase inhibitors (ARL67156, GdCl3, Suramin), parasites were
recovered after one VERO cell passage, washed in sterilized saline
solution and suspended in RPMI containing different concentra-
tions of inhibitors. After 10 min of exposure to the inhibitor,
parasites were recovered, suspended in new RPMI medium devoid
of inhibitor and used for infecting VERO cells monolayer. The
Vero cells were infected as described above. Samples of Y strain
P1 trypomastigotes were produced using independent sets of
mouse blood containing Y strain trypomastigotes.
T. cruzi in vivo infection assay (Virulence assay)
All procedures and experimental animal protocols were
conducted in accordance with the COBEA (Brazilian School of
Animal Experimentation) and behavior instructions for the use of
animals in research. For in vivo assays, groups of ten mice were
inoculated with 5610
3 culture-derived P1-trypomastigotes of Y T.
cruzi strain treated or not with ecto-nucleotidase inhibitors
ARL67156 (300 mM), GdCl3 (300 mM) or Suramin (100 mM
and 1000 mM). A second confirmatory assay was performed using
the same concentrations of ARL67156 (300 mM), GdCl3 (300 mM)
and only the most effective concentration of Suramin (1000 mM)
using groups of six mice. Treatment with inhibitors was performed
using 2610
5 parasites/ml during 10 min in MEM with 1% fetal
calf serum and the respective ecto-nucleotidase inhibitors. After
treatment parasites were recovered by centrifugation at 3500 rpm
for 15 min, suspended in the same medium without inhibitors and
used for infecting mice as described above. Parasitemia was
evaluated by examination of fresh blood collected from the mouse-
tail, starting from day 4
th post infection. The number of parasites
was calculated as previously described [30]. Curves were plotted
using the mean of the parasitemia obtained from six mice.
Mortality rate was cumulative and expressed as a percentage of
deaths within the period of 120 days after inoculation.
Statistical analysis
Except when mentioned, all hydrolytic activity experiments
were performed in triplicate, with similar results obtained in at
least three separate cell suspensions. Statistical significance was
determined by Student’s t test. Differences were considered
significant at p,0.05. Data were expressed as average6standard
deviation.
Results
Ecto-NTPDase activities are diverse in distinct strains of T.
cruzi
Blood trypomastigotes from Y, Be-62 and CL strains and the
clone CL-Brener were used for infecting VERO cell cultures.
Parasites obtained after one passage (P1) were used for measuring
Ecto-ATPDase hydrolytic activity. The different strains exhibited
distinct levels of ATP and ADP hydrolysis (Figure 1). Y strain
presented the highest levels of ATP hydrolysis and lowest ADP
Ecto-Nucleotidase and Trypanosoma Infection
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assays.
Y strain Ecto-NTPDase activity and infectivity decreases
during continuous VERO cells cultivation
In order to establish a possible correlation with ecto-nucleotidase
activity and infectivity capacity, we started a continuous in vitro
cultivation of Y trypomastigotes in VERO cell cultures and
analyzed Ecto-ATPDase activity. Each global exit of parasites to
the culture supernatant after completion of the intracellular life
cycle was named as ‘‘one passage (P)’’. Because Y is a polyclonal
strain we observed two days of massive parasite exit from VERO
cells; samples for each day of cell exit for the 1
st and 3
rd passages
werecollectedandcalled PN-X,were Nindicatesthepassage and X
indicates the day from the beginning of cell exit in each passage. We
detected a marked 3- to 6-fold decrease in the ATPase/ADPase
ratio (Figure 2A, inset) and in the number of parasites that infected
cells at the 3
rd to 4
th passage when compared to the 1
st passage
parasites (Figures 2B, 2C). Because of this observed low infection
from 3
rd to 4
th passage, we were unable to recover sufficient
parasites to perform enzymatic assays for the 5
th and later passages.
Curiously, ecto-ATPase activity ranged from 1400 to 2800 nmol
Pi.10
8 parasites
21.h
21 (P1, P3, P4) and it did not decrease
significantly in trypomastigotes that could complete infection and
intra cellularcycleinall analyzedpassages(Figure 2A).Onthe other
hand, ecto-ADPase activity increased from 50–100 nmol Pi.10
8
parasites
21.h
21 in the first passage to 300–1200 nmol Pi.10
8
parasites
21.h
21 in passages 3 and 4 (Figure 2A), reflecting in a
significantly decreased ecto-ATP/ADPase ratio (Figure 2A, inset).
We did not measure infectivity directly during passages
cultivation, but it could be clearly observed that the number of
parasites from the 3
rd to 4
th passage penetrating VERO cells was
very low. The majority of parasites did not infect cells and
differentiated to amastigote-like in the culture supernatant
(Figure 2B, 2C). We recovered these parasites and observed that
the population was comprised of about 80% amastigote-like and
20% trypomastigotes that could not penetrate VERO cells. We
compared the ecto-nucleotidase activity of these parasites
(indicated as Ama-like-P3 on Figure 2A) with that of infective P4
trypomastigotes (parasites that penetrated cells, concluded the
cellular life cycle and were recovered from VERO cell culture
supernatant). In Figure 2A (inset) we show that these non-
penetrating amastigote-like parasites have an ecto-ATPase/
ADPase ratio of 2.0, which is 2.5-fold lower than infective P4-
trypomastigotes (ratio=5.6). Overall, these results suggested that a
high ATPase/ADPase ratio (in the range of 12 to 36) seems to be a
requirement for internalization of parasites. We speculate that the
absence of mammalian host factors in the culture medium could
influence the differentiation process, generating non-infective
amastigote-like parasites with reduced Ecto-ATPDase activity.
Known ecto-ATPDase inhibitors decrease T. cruzi Ecto-
ATPDase activities and in vitro infectivity
In face of the above results, we decided to investigate the effect
of known ecto-ATDPase inhibitors on T. cruzi infectivity and
hydrolytic activity. We tested the action of Ecto-ATPDase
inhibitors directly on live P1-trypomastigotes from Y strain. The
inhibitors tested were: ARL67156 (6-N,N-Diethyl-b-c-dibromo-
methylene-D-adenosine-5-triphosphate) considered to be a selec-
tive inhibitor of ecto-ATPase [31]; Gadolinium, a lanthanide
related with extra- and intracellular ATP action and able to inhibit
Ecto-NTPDase from Torpedo electric organ [32] and Suramin, a
polysulfonated naphthylurea compound that was previously
demonstrated to inhibit T. cruzi Ecto-ATPDase [10].
Intact parasites were incubated for 10 min with different
concentrations of the above inhibitors (0, 100, 300, 500 mM)
and were subsequently recovered by centrifugation and suspended
in fresh buffer free of inhibitors. These pre-treated parasites were
used for in vivo Ecto-ATPDase hydrolysis assays and in
experimental VERO cells infection.
Figure 1. Ecto-nucleotidase activities of trypomastigotes from different strains/clone of T. cruzi. Trypomastigotes were obtained from
the first VERO cells passage (P1). The Ecto-ATPDase activities were measured at 37uC during 1 hour. Data are mean6SE of two independent
experiments in triplicate.
doi:10.1371/journal.pntd.0000387.g001
Ecto-Nucleotidase and Trypanosoma Infection
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ATPase and ADPase activities. Higher in vivo inhibition of T. cruzi
ecto-ATPase (approximately 75%) was achieved with Suramin
100 mM (Figure 3A). Gadolinium and ARL67156 inhibited only
approximately 30% of this activity at 300 and 500 mM respectively
(Figure 3B and 3C). On the other hand ADPase activity was more
effectively inhibited (60%) by Suramin and Gadolinium at
500 mM; ARL 67156 inhibited about 50% of ADPase activity at
300 mM (Figure 3A, 3B and 3C).
Infectivity of parasites treated with ATPDase inhibitors
(300 mM ARL 67156, 300 mM Gadolinium or 100 mM Suramin)
were evaluated in VERO cells. P1 trypomastigotes (Y strain) were
pre-treated during 10 min with the indicated inhibitor concentra-
tions. Parasites were recovered by centrifugation, washed in
Figure 2. T. cruzi infectivity and ecto-ATPase/ADPase ratio decrease during in vitro cultivation. A) Ecto-ATPDase (solid bars) and Ecto-
ADPDase (open bars) activities from live trypomastigotes from different cellular passages (P1, P3 and P4). P1-1 and P1-2 are the first and second
massive exits of parasites from the 1
st passage; in the same way P3-1 and P3-2 are the first and second massive exits of parasites for the 3
rd passage.
Data are mean6SE of triplicate assays from one experiment. The inset shows the ATPase/ADPase hydrolytic activities ratio. B) Microphotograph of
infected VERO cells culture after 24 h of parasite-cell interaction at the 3
rd to 4
th passage. Spherical bodies are non-internalized amastigote-like
parasites. C) Zoom from box section shown in B. Black arrow exemplifies a non-internalized amastigote-like and white arrow a non-internalized
trypomastigote parasite.
doi:10.1371/journal.pntd.0000387.g002
Ecto-Nucleotidase and Trypanosoma Infection
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ers. After 24 hours of interaction (parasites-cells) the non-
internalized parasites were discarded. The slides were covered
with new growth medium and incubated during an additional
24 h. After staining, levels of cell infection and the number of
intracellular amastigotes per infected cells were measured.
Suramin was the most effective in vitro infectivity inhibitor, as
revealed by a significant 71% reduction in the number of infected
cells per 300 cells (Table 1), which is also visually documented in
microphotographs of VERO cells exposed to control or Suramin
pre-treated parasites (Figures 4E and 4F, respectively). It should be
noted that pre-treatment of parasites with Suramin caused an
infectivity blockage while not affecting the intracellular survival of
those parasites that managed to penetrate the cells, as evidenced
by a similar number of parasites per infected cell detected in the
experiment (Table 1). ARL 67156 and Gadolinium caused 42%
and 65% infectivity inhibition, respectively (Table 1, Figure 4A,
4B, 4C, 4D). The results show that only Suramin and Gadolinium
lead to significant decrements in T. cruzi infectivity. These observed
effects resulted from a direct action of drugs on the parasite rather
than derived from a response of VERO cells to the drugs, since the
cells did not have direct contact with the drugs. Similar to Suramin,
ARL 67156 pre-treatment did not affect the detected number of
parasites per infected cell, whereas GdCl3 pre-treatment caused a
significant decrement in the number of parasites per infected cell
(Table 1). This latter observation could be related with the action of
GdCl3 inhibitor upon target biomolecules involved with both
infection and differentiation processes.
T. cruzi Ecto-NTPDase-1 is inhibited by Suramin
We have only identified one T. cruzi NTP-diphosphohydrolase in
the parasite genome, named NTPDase-1 [17]. In light of the results
described in the previous sections, we decided to study if NTPDase-
1 could be responsible for the Ecto-ATPDase activity correlated
with parasite infectivity. We obtained the recombinant T. cruzi
NTPDase-1 (,66 kDa) by heterologous expression, purified it by
affinity chromatography (Figure 5A) and evaluated its ATPDase
activity in presence or absence of the previously described Ecto-
NTPDase inhibitors. The specific ATPase and ADPase activities
were 24.068.4 and 14.366.9 nmol Pi. h
21 .mg Prot
21, or 0.4 and
0.24 mmolPi.min
21.mgProt
21. Specificactivities areinthe range of
recombinant human enzymes [33]. Concerning only the average
activity values the ATPase/ADPase ratio is 1.7, similar to mouse
(1.9) and human (1.9) NTPDase1 isoforms [33]. We show in
Figure5BthatonlySuramincausedsignificantlevelsofnucleotidase
inhibition of this enzyme. The level of Suramin inhibition on
recombinant purified NTPDase-1 (40 to 50%) was very similar to
the extent of Suramin inhibition of hydrolytic activity on live
parasites (Figure 3), suggesting that Suramin blockage of trypomas-
tigote infectivity (Table 1) could be related with its effect on T. cruzi
NTPDase-1. On the other hand ARL 67156 and Gadolinium
showed no effect on the activity of this recombinant enzyme,
suggesting that other enzymes with NTPDase activity sensitive to
these inhibitors may exist at the T. cruzi surface.
Figure 3. Effect of inhibitors in the ecto-ATPDase activity of Y
strain P1 trypomastigotes. Parasites were pre-incubated for 10 min
with different concentrations of Suramin (Panel A), ARL 67156 (Panel B)
or Gadolinium (Panel C) and ecto-ATPDase activities were measured.
Ecto-ATPase (D) and ecto-ADPase (%) activities are expressed as
percentage of control activity (without inhibitors). Data are mean6
standard error of two independent experiments in triplicate.
doi:10.1371/journal.pntd.0000387.g003
Table 1. Effect of apyrase inhibitors on in vitro infectivity of trypomastigotes.
Ecto-NTPDase Inhibitor # Parasites/infected cell # Infected cells/300 cells Infectivity Inhibition (%)
—+ — +
ARL 67156 (300 mM) 2.9560.32 2.3560.39 28.9265.50 17.5463.52 4261.17
Gadolinium (300 mM) 4.6560.38 3.4260.23* 106.1465.66 36.7268.71 6562.90*
Suramin (100 mM) 3.2060.52 3.2460.24 64.9363.65 13.1862.74 7160.85*
Percent inhibition of infection was calculated for each inhibitor assay relative to control data. Data reflect the mean6SE from three analyzed slides. Asterisks indicate
significant differences (p,0.05) between the control without inhibitor and the test with ATPDase inhibitor.
doi:10.1371/journal.pntd.0000387.t001
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www.plosntds.org 6 March 2009 | Volume 3 | Issue 3 | e387Figure 4. Effects of ecto-ATPDase inhibitors on in vitro T. cruzi infectivity. Microphotographs of VERO cell monolayers infected with
trypomastigotes not treated (panels A,C,E) or treated with Ecto-ATPDase inhibitors (panels B,D,F). P1 trypomastigotes (Y strain) were pre-treated with
ARL 67156, Gadolinium or Suramin at the indicated concentrations, resuspended in medium without inhibitor and used in VERO cells invasion assays.
After 24 hours post infection each assay slide was washed and stained with Giemsa. The arrows indicate many internalized amastigotes.
doi:10.1371/journal.pntd.0000387.g004
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inhibited in vitro T. cruzi infection
We produced a polyclonal antiserum anti- T. cruzi NTPDase-1
using the purified recombinant protein as antigen for immunization
of rabbits. This serum gives a strong signal in immuno-fluorescence
experiments; in contrast no signal is obtained from the negative
control pre-immune serum, thus clearly indicating that immuniza-
tion of rabbits with the antigen has produced antibodies against
NTPDase-1 (Cunha et al., manuscript in preparation).
In vitro assays using the antiserum fail to produce any inhibitory
action towards the recombinant protein enzymatic activity (data
not shown). This indicates that although the produced antibodies
are able to bind to NTPDase-1, they must target regions that are
not essential for enzymatic activity.
A complement system (CS) inhibition pre-treatment of the pre-
immune and immune sera was performed as described in material
and methods, before its use in infectivity assays. Y strain P1
trypomastigotes were submitted to pre-incubation with CS
inactivated antisera, and parasites were used for infecting VERO
cell monolayers. We observed that the antiserum assayed at 1:50
and1:100significantlyinhibitedthe infectivityofparasites(Table2).
Ecto-NTPDase inhibitors decrease T. cruzi mouse
infection and virulence
To confirm the results from experiments using VERO cells as
model, we performed experimental in vivo infection assays in mice
using P1 Y trypomastigotes pre-treated with the optimal
concentration of Ecto-NTPDase inhibitors that blocked in vitro
infection (Table 1 and Figure 4). A parallel negative control
experiment was performed by omitting drug pre-treatment of
parasites. All data are mostly related with the action of drugs
directly on parasites rather than on mice, because parasites are
pre-treated with inhibitors, washed and finally inoculated in the
animals. Figures 6A and B show the parasitemia and mortality
verified in the tested animals, respectively. Data clearly shows that
pre-exposure of parasites to ARL 67156 (300 mM) or Gadolinium
(300 mM) resulted in a decreased parasitemia and increased host
animal’s survival. The most effective drug was ARL 67156, which
resulted in about 60% mice survival when compared with mice
infected with non-treated parasites (control). Pre-treatment of
parasites with Suramin at 100 mM (data not shown) and 300 mM
(Figure 6B) did not result in significant protection, while pre-
exposure of parasites to 1 mM Suramin resulted in a significant
decrease in parasitemia as well as a prolonged time of survival of
infected mice (Figure 6A, 6B). A second confirmatory experiment
was performed and gave similar results (data not shown).
Discussion
The present work shows evidence that continuing cultivation of
trypomastigotes in VERO cells caused an infectivity decrease
during cultivation and that only a small fraction of parasites was
able to infect VERO cells and conclude another cellular cycle at
the third to fourth passage. Parasites (trypomastigotes) that
completed this passage presented 2.5-fold higher levels of ecto-
ATPase activities when compared with amastigote-like parasites
that could not penetrate into VERO cells. These data reinforce
that a high ecto-ATPase activity is important for infectivity and
suggest that the absence of host factors leads to loss of infectivity
factors from T. cruzi. Similar suggestion was made by Be ˆrredo-
Pinho et al. [14] when the ecto-ATPase activity was assayed on
promastigotes from Leishmania amazonensis and showed that higher
passages in acellular medium lead to low ecto-ATPase levels and
avirulence [14]. However, as we have used a single strain (Y) in
our experiments, verification of correlation between infectivity and
Ecto-ATPDase activity in other strains may provide further
support to our hypothesis.
In order to evaluate the importance of Ecto-NTPDase activity
in T. cruzi infectivity we performed experiments with three known
enzyme inhibitors. Analyzing Ecto-ATPDase inhibitory effects of
these compounds we observed that all were able to partially inhibit
both ecto-ATPase and -ADPase on live parasites, but the effect of
ARL67156 and Gadolinium on the ecto-ATPase was lower than
that observed for Suramin. In parallel, we observed that P1
trypomastigotes treated with ecto-nucleotidase inhibitors showed
significant decrements of in vitro infectivity (Table 1) and in vivo
virulence (Figure 6), suggesting the importance of Ecto-ATPDase
activity in these processes. We cannot exclude the possibility that
Figure 5. Heterologous expression of T. cruzi Ecto-NTPDase-1
and the effect of ecto-ATPase inhibitors on purified protein. A)
SDS-PAGE stained with coomassie blue. A 15 mL sample of each step of
production and purification of Ecto-NTPDase-1 was applied in each
lane, showing the purified protein with approx. 66 kDa. MW, molecular
weight markers. B) ATPDase activity of purified Ecto-NTPDase-1 in the
presence of ecto-ATPase inhibitors. The results represent the percent
activity with inhibitor related to the activities in the absence of
inhibitors. Data are mean6SE of two independent experiments, each
assayed in triplicate.
doi:10.1371/journal.pntd.0000387.g005
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Antiserum anti-NTPDase-1-HexaHIS Pre-immune serum
1:50 1:100 1:50 1:100
—+—+— + — +
# Parasites/infected cell 2.1160.31 2.0460.50 1.4760.30 2.2060.13 5.8860.82 6.4061.30 5.8860.82 5.3460.76
# Infected cells/300 cells 18.963.22 8.8361.75 17.463.53 8.9661.16 109.066.62 135.0617.1 109.066.62 122.1611.5
Infected cells inhibition (%) 5360.58* 4960.38* 0 0
*Percent inhibition of infection was calculated for each inhibition assay relative to control data. Data reflect the mean6SE from three analyzed slides. Asterisks indicate
significant differences (p,0.05) between the control without antiserum (2) and the tests with antiserum (+).
doi:10.1371/journal.pntd.0000387.t002
Figure 6. Inhibition of T. cruzi Ecto-ATPDases decreased virulence to mouse. A) parasitemia curves and B) mortality in Swiss mice infected
with 5,000 parasites/0.1 mL blood (Y strain P1 trypomastigotes). Parasites were pre-treated with ARL67156, Gadolinium or Suramin as indicated; a
negative control assay is included, omitting the parasites’ drug pre-treatment. Data are from one experiment using the mean value of a group of 10
mice in each treatment.
doi:10.1371/journal.pntd.0000387.g006
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molecular targets. It has been shown that P2 receptors are
susceptible to blockage by Suramin [34], but even if that is the case
our data would still point out the importance of the extracellular
nucleotide metabolism for T. cruzi, as demonstrated for other
parasites [35]. Further studies including the use of more selective
ENTPDase inhibititors, such as Polyoxometalates [36] and
anthraquinone derivatives from bromaminic acid [37], are still
necessary to determine the exact molecular mechanism inducing
the loss of infectivity and virulence observed in our experiments.
Parasites have been incubated with high concentrations of
inhibitor, but the in vitro experiments were performed in drug-free
medium after the centrifugation of parasites. The persistence of
effects from drugs on the parasite even after their removal suggests
that the drugs might have triggered persistent changes in the
parasite’s metabolism that had a very slow recovery rate.
Considering the important roles of ATP, ADP and Adenosine as
extracellular molecules in modulating the inflammatory process
and platelet aggregation [5,38–40] and the proposed role of
NTPDases in host pathogen interactions [41], it is possible to
speculate that some of the in vivo effects observed might be
correlated to the impairment of the parasites’ ability to modulate
the levels of these nucleotides by inhibition of NTPDase. Further
experiments are warranted to substantiate this hypothesis.
The present work shows the first biochemical demonstration of
recombinant T. cruzi Ecto-NTPDase-1 activity. Enzymatic inhibi-
tion of this recombinant protein in the presence of Suramin,
suggests that the effects of this drug on intact parasites, namely
blockage of cell infection may be due to targeting of this inhibitor
to the Ecto-NTPDase-1 on their surface. Polyclonal antiserum to
T.cruzi Ecto-NTPDase also blocked infection of the cells. It should
be noted that the antibodies did not display any direct inhibitory
effect on enzymatic activity of the recombinant NTPDase-1, under
controlled in vitro conditions. Considering that during the infection
process the parasite will be exposed to diverse environmental
conditions, it is possible that even though the antibody was not
directly targeted to the NTPDase-1 active site, it might bind to
modulatory regions preventing the response of the enzyme to
certain stimuli. Alternatively, antibody binding might generate a
steric hindrance at the parasite surface that prevents its adhesion
to host cells.
Structural studies of NTPDase-1 and its use for the rational
design of inhibitors could be a relevant strategy for the
development of new drugs to treat the disease. In addition, the
observed effect of antibodies on the parasites suggests that an
effective immune response from the host could be mounted based
on vaccination using this antigen. Further immunization experi-
ments using this protein are necessary to verify its potential as a
protective antigen.
In contrast, the observed ARL 67156 and Gadolinium
inhibition of hydrolytic activities on live parasites could be related
with another ecto-nucleotidase target, since they caused no
inhibition of purified T. cruzi Ecto-NTPDase-1; this observation
suggests the existence of other enzymes with Ecto-NTPDase
activity at the parasite surface. We exhaustively searched for
another apyrase/CD39 gene in the T. cruzi genome public
database, including the in silico screening of 67 Mb of partial
genome assembly [42] without any success. This indicates that
targets for ARL 67156 and Gadolinium are either Ecto-NTPDases
encoded by genes that are located in a portion of the genome not
yet sequenced or are proteins with no detectable primary sequence
similarity with Ecto-NTPDase. Alternatively, it is possible that
Ecto-NTPDase-1 is in fact inhibited by these other compounds,
but the recombinant version of this protein is insensitive due to
alterations in its structure compared to the native form.
This paper shows the correlation of Ecto-ATPDase activity with
T. cruzi infectivity and virulence. In addition, inhibitors of such
activity tested here appear to interfere with the parasite infection
process and emerge as possible new clinical drugs to Chagas
disease treatment. Because Suramin and Gadolinium are currently
used in unrelated human chemotherapy these drugs have already
been tried for safety and may provide prompt options for
development and use in Chagas disease treatment. Suramin is a
current drug used in the treatment of Human African trypano-
somiasis [43] and exhibits toxic effects to T. cruzi [44,45].
Gadolinium is used as a contrast drug in magnetic resonance
clinical imaging exams. (Gd)-based paramagnetic contrast agents
are relatively safe when used in clinically recommended doses,
however there is literature linking Gd-based paramagnetic
contrast agents with nephrogenic systemic fibrosis (NSF) in
patients with renal failure [46]. We believe that chemotherapy
studies with these compounds and their association with the
currently used drug Benznidazole in lower doses is warranted and
may represent an alternative to treat Chagas patients.
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